Dupilumab improve acquired reactive perforating collagenosis characterized by type 2 inflammation

BACKGROUND: Acquired reactive perforating collagenosis (ARPC) is a clinically challenging disease with an unclear pathogenesis. OBJECTIVE: To evaluate the efficacy and safety of dupilumab for the treatment of ARPC, and analyze the expression of type 2 inflammation-related molecules in ARPC lesions....

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ben, Wu, Yibei, Wu, Xiaoyan, Zhong, Xinyu, Xue, Ruzeng, Zhang, Zhenying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449391/
https://www.ncbi.nlm.nih.gov/pubmed/37638036
http://dx.doi.org/10.3389/fimmu.2023.1240262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449391/
https://www.ncbi.nlm.nih.gov/pubmed/37638036
http://dx.doi.org/10.3389/fimmu.2023.1240262

Ejemplares similares